
Nicholas A. Mcfall
Examiner (ID: 12083, Phone: (571)270-5769 , Office: P/3644 )
| Most Active Art Unit | 3644 |
| Art Unit(s) | 3644 |
| Total Applications | 701 |
| Issued Applications | 585 |
| Pending Applications | 54 |
| Abandoned Applications | 75 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18707478
[patent_doc_number] => 20230330052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITION OF ACTIVE AGENTS TO POSITIVELY AFFECT A ROBUST MAMMALIAN ENDOCANNABINOID SYSTEM TONE TO BETTER ADDRESS AGE RELATED DISCOMFORT
[patent_app_type] => utility
[patent_app_number] => 18/214137
[patent_app_country] => US
[patent_app_date] => 2023-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14772
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18214137
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/214137 | COMPOSITION OF ACTIVE AGENTS TO POSITIVELY AFFECT A ROBUST MAMMALIAN ENDOCANNABINOID SYSTEM TONE TO BETTER ADDRESS AGE RELATED DISCOMFORT | Jun 25, 2023 | Abandoned |
Array
(
[id] => 18672919
[patent_doc_number] => 20230310368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => MDMA ENANTIOMERS
[patent_app_type] => utility
[patent_app_number] => 18/331682
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331682
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/331682 | MDMA ENANTIOMERS | Jun 7, 2023 | Abandoned |
Array
(
[id] => 18675076
[patent_doc_number] => 20230312648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/112663
[patent_app_country] => US
[patent_app_date] => 2023-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22612
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18112663
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/112663 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | Feb 21, 2023 | Pending |
Array
(
[id] => 18321013
[patent_doc_number] => 20230119141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => USES OF TAXIFOLIN FOR RESPIRATORY HEALTH
[patent_app_type] => utility
[patent_app_number] => 18/047742
[patent_app_country] => US
[patent_app_date] => 2022-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7858
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047742
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047742 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | Oct 18, 2022 | Abandoned |
Array
(
[id] => 18496052
[patent_doc_number] => 20230218587
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/963838
[patent_app_country] => US
[patent_app_date] => 2022-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16437
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17963838
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/963838 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | Oct 10, 2022 | Abandoned |
Array
(
[id] => 17837689
[patent_doc_number] => 20220274994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/740877
[patent_app_country] => US
[patent_app_date] => 2022-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740877 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | May 9, 2022 | Abandoned |
Array
(
[id] => 18036163
[patent_doc_number] => 20220380378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
[patent_app_type] => utility
[patent_app_number] => 17/727054
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727054
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727054 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | Apr 21, 2022 | Abandoned |
Array
(
[id] => 19464183
[patent_doc_number] => 20240317852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => NOVEL DARPIN BASED CD33 ENGAGERS
[patent_app_type] => utility
[patent_app_number] => 18/281156
[patent_app_country] => US
[patent_app_date] => 2022-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281156
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/281156 | NOVEL DARPIN BASED CD33 ENGAGERS | Mar 8, 2022 | Pending |
Array
(
[id] => 18860072
[patent_doc_number] => 20230414506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => PEPTIDE FORMULATIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/035846
[patent_app_country] => US
[patent_app_date] => 2021-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14445
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035846
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/035846 | PEPTIDE FORMULATIONS AND METHODS OF USE | Nov 2, 2021 | Pending |
Array
(
[id] => 17472457
[patent_doc_number] => 20220079961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => NASAL SPRAY FORMULATIONS USING BOTANICALS, STEROIDS ORGANOSILANE QUATERNARIES, POLYOL STABILIZING AGENTS AND NONIONIC SURFACTANT AS ANTIMICROBIALS, ANTIVIRALS AND BIOCIDES TO PROTECT THE CELLS, SKIN AND HAIR OF NASAL PASSAGES
[patent_app_type] => utility
[patent_app_number] => 17/476768
[patent_app_country] => US
[patent_app_date] => 2021-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17476768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/476768 | NASAL SPRAY FORMULATIONS USING BOTANICALS, STEROIDS ORGANOSILANE QUATERNARIES, POLYOL STABILIZING AGENTS AND NONIONIC SURFACTANT AS ANTIMICROBIALS, ANTIVIRALS AND BIOCIDES TO PROTECT THE CELLS, SKIN AND HAIR OF NASAL PASSAGES | Sep 15, 2021 | Abandoned |
Array
(
[id] => 18550802
[patent_doc_number] => 20230248802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VITILIGO
[patent_app_type] => utility
[patent_app_number] => 18/014660
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014660
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014660 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VITILIGO | Jun 22, 2021 | Pending |
Array
(
[id] => 17990143
[patent_doc_number] => 20220356180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
[patent_app_type] => utility
[patent_app_number] => 17/244938
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244938
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/244938 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Apr 28, 2021 | Abandoned |
Array
(
[id] => 18769296
[patent_doc_number] => 20230364053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 18/246522
[patent_app_country] => US
[patent_app_date] => 2021-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 315
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246522
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246522 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | Apr 19, 2021 | Abandoned |
Array
(
[id] => 18242813
[patent_doc_number] => 20230075124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => AEROSOL COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
[patent_app_type] => utility
[patent_app_number] => 17/801389
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/801389 | AEROSOL COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Feb 23, 2021 | Pending |
Array
(
[id] => 18321007
[patent_doc_number] => 20230119135
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PREMENSTRUAL SYNDROME (PMS)
[patent_app_type] => utility
[patent_app_number] => 17/904955
[patent_app_country] => US
[patent_app_date] => 2021-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904955
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/904955 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PREMENSTRUAL SYNDROME (PMS) | Feb 22, 2021 | Abandoned |
Array
(
[id] => 16807810
[patent_doc_number] => 20210130363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/146855
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16163
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/146855 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | Jan 11, 2021 | Abandoned |
Array
(
[id] => 18595902
[patent_doc_number] => 20230270692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => COMPOUNDS FOR CHRONIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/792020
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792020 | COMPOUNDS FOR CHRONIC DISORDERS | Jan 10, 2021 | Pending |
Array
(
[id] => 16822576
[patent_doc_number] => 20210137869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => CYSTEINE COMPOSITION AND INJECTION
[patent_app_type] => utility
[patent_app_number] => 17/139420
[patent_app_country] => US
[patent_app_date] => 2020-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17139420
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/139420 | CYSTEINE COMPOSITION AND INJECTION | Dec 30, 2020 | Abandoned |
Array
(
[id] => 16898928
[patent_doc_number] => 20210177844
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
[patent_app_type] => utility
[patent_app_number] => 17/123777
[patent_app_country] => US
[patent_app_date] => 2020-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17123777
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/123777 | Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer | Dec 15, 2020 | Abandoned |
Array
(
[id] => 18309654
[patent_doc_number] => 20230113554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => NON-STICK ANTIBIOTIC GELS
[patent_app_type] => utility
[patent_app_number] => 17/802992
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7501
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802992 | NON-STICK ANTIBIOTIC GELS | Dec 9, 2020 | Pending |